AtriCure shares soar as Q2 results beat estimates, guidance raised

Published 29/07/2025, 21:22
AtriCure shares soar as Q2 results beat estimates, guidance raised

Investing.com -- AtriCure , Inc. (NASDAQ:ATRC), a provider of surgical treatments for atrial fibrillation and related conditions, reported second quarter earnings that exceeded analyst expectations and raised its full-year outlook, sending shares surging 15% in trading.

The company posted a second quarter loss of -$0.13 per share, beating analyst estimates of -$0.17 per share. Revenue jumped 17.1% YoY to $136.1 million, surpassing the consensus estimate of $130.17 million. The strong performance was driven by growing adoption across the company’s product portfolio, particularly its AtriClip platform and cryoSPHERE devices.

U.S. revenue increased 15.7% to $110.6 million, while international revenue grew 23.3% to $25.6 million. The company’s adjusted EBITDA reached $15.4 million, up significantly from the same period last year.

"Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio," said Michael Carrel, President and CEO at AtriCure. "We’re seeing increasing momentum as our new technologies drive deeper adoption, reduced procedure times, and improved patient outcomes."

Following the strong quarter, AtriCure raised its full-year 2025 guidance, now projecting revenue between $527 million and $533 million, above the previous analyst consensus of $523 million. The company also improved its full-year adjusted loss per share forecast to between -$0.39 and -$0.34, better than analysts’ expectations of -$0.51.

Gross profit for the quarter was $101.5 million with a gross margin of 74.5%, representing a slight decrease of 15 basis points from the second quarter of 2024 due to less favorable geographic and product mix.

The company now expects to generate modest positive cash flow for the full year 2025, further strengthening its financial position as it continues to expand its product offerings for atrial fibrillation, left atrial appendage management, and post-operative pain management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.